Prediction of Stroke in Heart Failure: Is There a “One Size Fits All” Approach?

HomeCirculation: Heart FailureVol. 16, No. 7Prediction of Stroke in Heart Failure: Is There a “One Size Fits All” Approach? No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextPrediction of Stroke in Heart Failure: Is There a “One Size Fits All” Approach? Phillip H. Lam and C. Anwar A. Chahal Phillip H. LamPhillip H. Lam Correspondence to: Phillip H. Lam, MD, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010. Email E-mail Address: [email protected] Department of Cardiology, MedStar Heart and Vascular Institute, Washington, DC (P.H.L.). Georgetown University, Washington, DC (P.H.L.). Search for more papers by this author and C. Anwar A. ChahalC. Anwar A. Chahal https://orcid.org/0000-0001-7825-8827 Department of Cardiology, WellSpan Heart and Vascular Center, York, PA (C.A.A.C.). Barts Heart Centre, London, United Kingdom (C.A.A.C.). Search for more papers by this author Originally published23 Jun 2023https://doi.org/10.1161/CIRCHEARTFAILURE.123.010762Circulation: Heart Failure. 2023;16This article is a commentary on the followingPredicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationFootnotesFor Disclosures, see page 576.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Phillip H. Lam, MD, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC 20010. Email phillip.h.[email protected].netREFERENCES1. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association.Circulation. 2022; 145:e153–e639. doi: 10.1161/CIR.0000000000001052LinkGoogle Scholar2. Wafa HA, Wolfe CDA, Emmett E, Roth GA, Johnson CO, Wang Y. Burden of stroke in Europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years.Stroke. 2020; 51:2418–2427. doi: 10.1161/STROKEAHA.120.029606LinkGoogle Scholar3. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure.Nat Rev Cardiol. 2016; 13:131–147. doi: 10.1038/nrcardio.2015.191CrossrefMedlineGoogle Scholar4. Kondo TJKJ P, Anand I, Desai A, Lam C, Pietro A, Martinez F, Packer M, Petrie M, Pfeffer M, Redfield M, et al. Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation.Circ Heart Fail. 2023; 16:564–573. doi: 10.1161/CIRCHEARTFAILURE.122.010377LinkGoogle Scholar5. Kondo T, Abdul-Rahim AH, Talebi A, Abraham WT, Desai AS, Dickstein K, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.Eur Heart J. 2022; 43:4469–4479. doi: 10.1093/eurheartj/ehac487CrossrefMedlineGoogle Scholar6. Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, et al; Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) trials.Circulation. 2015; 131:1486–94; discussion 1494. doi: 10.1161/CIRCULATIONAHA.114.013760LinkGoogle Scholar7. Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, et al; Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity-Preserved (CHARM-Preserved) and the Irbesartan in Heart Failure with Preserved Systolic Function (I-Preserve) Steering Committees. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.Eur Heart J. 2017; 38:742–750. doi: 10.1093/eurheartj/ehw509CrossrefMedlineGoogle Scholar8. Rost NS, Bottle A, Lee JM, Randall M, Middleton S, Shaw L, Thijs V, Rinkel GJ, Hemmen TM; Global Comparators Stroke GOAL collaborators. Stroke severity is a crucial predictor of outcome: an international prospective validation study.J Am Heart Assoc. 2016; 5:e002433. doi: 10.1161/JAHA.115.002433LinkGoogle Scholar9. Vinding NE, Kristensen SL, Rorth R, Butt JH, Ostergaard L, Olesen JB, Torp-Pedersen C, Gislason GH, Kober L, Kruuse C, et al. Ischemic stroke severity and mortality in patients with and without atrial fibrillation.J Am Heart Assoc. 2022; 11:e022638. doi: 10.1161/JAHA.121.022638LinkGoogle Scholar10. Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB; APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores.Heart. 2014; 100:1524–1530. doi: 10.1136/heartjnl-2013-305303CrossrefMedlineGoogle Scholar11. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, et al; COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease.N Engl J Med. 2018; 379:1332–1342. doi: 10.1056/NEJMoa1808848CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesPredicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial FibrillationToru Kondo, et al. Circulation: Heart Failure. 2023;16 July 2023Vol 16, Issue 7 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.123.010762PMID: 37350258 Originally publishedJune 23, 2023 Keywordsatrial fibrillationHFpEFstrokeEditorialsPDF download Advertisement SubjectsBiomarkersClinical Studies